#AUA20 Summer Series - What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer (2020)
AUA - American Urological Association
America/New York GMT -4 summer
This course will include case-based presentations and ARS in three distinct diseases groups: hormone-sensitive metastatic prostate cancer (HSMPC); non-metastatic castrate resistant prostate cancer (M0CRPC) and metastatic CRPC (MCRPC) to educate urologists, APP's and their teams to identify and understand the many new FDA-approved agents, as well as existing standard therapies. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed. We aim to allow urologists and their practice teams to be comfortable prescribing various agents and understand systemic chemotherapy, PARP inhibitors and emerging immunotherapy. Of particular interest are the new FDA-approvals for these patients in the last year for use in HSMPC and MOCRPC.
Judd W. Moul
What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer (2020)
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Lawrence I. Karsh, Evan Y. Yu